Weekly Digest – May 2025 Weekly Digest – May 2025 08 May 2025: AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer in India AstraZeneca received CDSCO approval in India to import and sell […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: Adcentrx Therapeutics granted Fast Track Designation for ADRX-0706 nectin-4 ADC for the treatment of advanced cervical cancer Adcentrx Therapeutics received FDA Fast Track designation for its lead […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: IDEAYA Biosciences announces US FDA IND-clearance for IDE849, a potential first-in-class DLL3 TOP1 ADC, for a Phase 1 study in solid tumors IDEAYA Biosciences received FDA clearance […]
Weekly Digest – May 2025 Weekly Digest – May 2025 07 May 2025: ENHERTU (Trastuzumab deruxtecan) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer […]
Weekly Digest – May 2025 Weekly Digest – May 2025 05 May 2025: VERAXA Biotech enters co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program VERAXA Biotech has entered into a co-discovery alliance with OmniAb to develop […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: Formosa Pharmaceuticals and Almac Discovery announce licensing agreement for ALM-401, a first-in-class Bispecific ADC targeting EGFR/ROR1 for the treatment of solid tumors Formosa Pharmaceuticals has secured exclusive […]
